title: Current status of predictive biomarkers for neoadjuvant therapy in esophageal cancer.
abstract: Neoadjuvant therapy has been proven to be extremely valuable and is widely used for advanced esophageal cancer. However, a significant proportion of treated patients (60%-70%) does not respond well to neoadjuvant treatments and develop severe adverse effects. Therefore, predictive markers for individualization of multimodality treatments are urgently needed in esophageal cancer. Recently, molecular biomarkers that predict the response to neoadjuvant therapy have been explored in multimodal approaches in esophageal cancer and successful examples of biomarker identification have been reported. In this review, promising candidates for predictive molecular biomarkers developed by using multiple molecular approaches are reviewed. Moreover, treatment strategies based on the status of predicted biomarkers are discussed, while considering the international differences in the clinical background. However, in the absence of adequate treatment options related to the results of the biomarker test, the usefulness of these diagnostic tools is limited and new effective therapies for biomarker-identified nonresponders to cancer treatment should be concurrent with the progress of predictive technologies. Further improvement in the prognosis of esophageal cancer patients can be achieved through the introduction of novel therapeutic approaches in clinical practice.
authors.affiliation: Norihisa Uemura, Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya 464-8681, Aichi, Japan.
authors.forename: Norihisa
authors.initials: N
authors.lastname: Uemura
authors.affiliation: Norihisa Uemura, Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya 464-8681, Aichi, Japan.
authors.forename: Tadashi
authors.initials: T
authors.lastname: Kondo
keywords: Chemoradiation; Esophageal cancer; Molecular biomarker; Neoadjuvant therapy; Response prediction